Navigation Links
Pfenex Inc. Announces Pricing Of Initial Public Offering
Date:7/23/2014

SAN DIEGO, July 24, 2014 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX) today announced the pricing of its initial public offering of 8,333,333 shares of its common stock at a price to the public of $6.00 per share. In addition, Pfenex has granted the underwriters a 30-day option to purchase up to 1,250,000 additional shares of common stock at the initial public offering price. The shares are expected to begin trading on the NYSE MKT on July 24, 2014, under the symbol "PFNX".

William Blair & Company, L.L.C. and JMP Securities LLC are acting as joint book-running managers for the offering and Mizuho Securities USA Inc. is acting as a co-manager.

A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. The offering is being made only by means of a prospectus. A copy of the final prospectus relating to the offering may be obtained from William Blair & Company, L.L.C., Attention: Prospectus Department, 222 West Adams Street, Chicago, IL 60606, or by calling (800) 621-0687 or by emailing a request to prospectus@williamblair.com; or from JMP Securities LLC, Attention: Prospectus Department, 600 Montgomery Street, 10th Floor, San Francisco, CA 94111, or by calling (415) 835-8985.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Pfenex Inc.
Pfenex Inc. is a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins including biosimilar therapeutics. The company's lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfēnex Expression Technology™ platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics.  

Logo - http://photos.prnewswire.com/prnh/20140715/127348


'/>"/>
SOURCE Pfenex Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology news :

1. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract and Increase Funding for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
2. Elsevier announces the launch of open access journal: Bone Reports
3. Elsevier announces launch of new journal: Current Opinion in Insect Science
4. SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT
5. Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors
6. BrightFocus Foundation announces 55 new grantees in Alzheimers and vision research
7. Elsevier Announces the launch of open access journal: New Negatives in Plant Science
8. Institute of Physics announces 2014 award winners
9. Elsevier announces the launch of a new journal: Current Opinion in Behavioral Sciences
10. Autism speaks announces Meixner Postdoctoral Fellowships in translational research
11. Ecological Society of America announces 2014 Fellows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2018)... Calif. (PRWEB) , ... August 21, 2018 , ... ... engineer the genomes of diverse cell types and species for the robust functional ... research tool for the development of T-cell based immunotherapies, the study of the ...
(Date:8/23/2018)... ... ... is proud to have hosted a variety of groups this year – both new guests ... Hewlett Packard, Sequenom and more, have all visited the La Jolla-based venue time and time ... reason clientele return is due to Lajollacooks4u’s signature team-building format, a way for teams to ...
(Date:8/21/2018)... ... August 20, 2018 , ... ... for biopharma R&D, today announced that Seattle-based Aptevo Therapeutics , a ... Aptevo will use the Genedata Biologics ® platform to facilitate expansion ...
Breaking Biology News(10 mins):
(Date:8/31/2018)... ... August 30, 2018 , ... Small, wireless and networked describes more ... and getting connected, too. Draper’s latest system is tiny in size, but is poised ... driving factor in the new implant design is the growing awareness that disease often ...
(Date:8/29/2018)... ... August 28, 2018 , ... Inc. Magazine has announced that ... in 1138th place on the 27th annual Inc. 5000, the most prestigious ranking ... most successful companies within the American economy’s most dynamic segment – independent small ...
(Date:8/29/2018)... SANTA BARBARA, Calif. (PRWEB) , ... August 28, 2018 , ... ... process optimization firm for the life sciences and healthcare industries, announces that Manu Vohra ... CA on August 30th. , What: “How to Implement Box for GxP in ...
(Date:8/23/2018)... , ... August 22, 2018 , ... ... for Android on September 1st, making it the first fully-featured app for electronic ... Android devices. Combined, iOS and Android constitute 99 percent of the market share ...
Breaking Biology Technology: